Furthermore, 6-month OS and PFS rates of recurrent and/or metastatic HNSCC patients treated with pembrolizumab, an anti-PD-1 monoclonal antibody, were 23% and 59%, respectively, showing a favorable response similar to single-drug cetuximab [22, 23]. The gene discussed is PDCD1; the disease is head and neck squamous cell carcinoma.